The US Food and Drug Administration has approved Moderna's mRNA seasonal influenza vaccine, mFlusiva (mRNA-1010), for adults aged 50 and older, making it the first seasonal influenza vaccine built on mRNA technology to reach the US market. The approval arrives in time for the 2026-27 flu season. (Engadget, New York Times)

The regulatory path was not straightforward. The FDA initially refused to review Moderna's application, arguing that the company's chosen comparator vaccine did not represent the best available standard of care in the US and that a higher-dose vaccine for older adults would have been the more appropriate benchmark. The agency reversed course less than a week later and agreed to take up the application. (Engadget, CIDRAP)

The approval spans two regulatory pathways. For adults aged 50 to 64, mFlusiva received standard approval on the basis of a Phase 3 clinical trial that enrolled 40,805 participants across 11 countries. For those aged 65 and older, the FDA granted accelerated approval, a pathway that permits earlier market access based on a surrogate or intermediate endpoint deemed reasonably likely to predict clinical benefit, with a post-approval commitment to confirm efficacy. Moderna had sought accelerated approval for the older cohort, and FDA staff had stated in briefing documents that the data "may support" effectiveness in that population. (Engadget, Reuters)

An FDA Advisory Committee voted unanimously in favor of the vaccine's benefit-risk profile prior to approval. (Moderna)

mFlusiva targets the four most common influenza strains, matching the quadrivalent composition of conventional seasonal flu vaccines. Moderna's Phase 3 study concluded that mRNA-1010 was superior to standard-dose licensed vaccines in preventing influenza-like illness in adults aged 50 and older. FDA briefing documents reported 47.9% efficacy (95% CI: 12.8, 68.9) against a study endpoint, which the agency characterized as supporting clinical meaningfulness. (Engadget, FDA, PubMed)

The vaccine has been in human testing since 2021. Moderna has also initiated a two-season Phase 3 trial to generate additional efficacy data across consecutive influenza cycles. (Engadget, Moderna Investor Relations)

FDA documents stated explicitly that approval of mRNA-1010 would provide a seasonal influenza vaccine platform to support influenza pandemic preparedness, positioning the technology as infrastructure for rapid response to future outbreak scenarios. (FDA)

The broader context here extends beyond a single product approval. Moderna had filed a Biologics License Application for mRNA-1083, a combination influenza and COVID-19 vaccine, in early 2025, then voluntarily withdrew that application in May 2025. The mFlusiva approval reestablishes a regulatory foothold for Moderna's non-COVID mRNA pipeline and provides a validated platform that combination vaccines like mRNA-1083 could build on in future submissions. (Moderna Investor Relations, January 2025, Moderna Investor Relations, May 2025)

The regulatory friction over the comparator vaccine is worth noting. The FDA's initial objection centered on trial design rigor: Moderna measured mRNA-1010 against a standard-dose flu vaccine when the agency believed the appropriate benchmark for older adults was a higher-dose, adjuvanted, or recombinant formulation already standard of care in that age group. That the agency ultimately accepted the data anyway, granting at least accelerated approval across the full 50-plus population, suggests the efficacy signal was strong enough to overcome the methodological objection, though the split pathway, standard approval for 50-64 and accelerated for 65-plus, reflects the residual uncertainty in the older cohort.

The pandemic-preparedness rationale embedded in the FDA's own documents is the element most likely to have long-term consequence. A licensed seasonal mRNA flu vaccine gives manufacturers and regulators a pre-validated platform for rapid strain-specific vaccine production in the event of an influenza pandemic, where compressed timelines are the defining variable. Whether that preparedness value materializes depends on manufacturing scale, public uptake, and the continued accumulation of real-world effectiveness data across seasons, all of which remain open questions as mFlusiva enters its first commercial flu season.